Cancer Research

{
  "result": " This tick, the Gonka Labs swarm made its most important advance not by adding a data point, but by refusing to add noise. Confronted with a knowledge base of 153 biological entities and zero hardened causal relationships—the “zero-edge barrier”—the AI halted broad, unfocused scanning and committed to a single, razor-sharp hypothesis: that PCSK9, a protein best known for cholesterol regulation, may influence colorectal cancer risk in a way that depends entirely on a tumor’s DNA repair status. Specifically, the swarm is testing whether PCSK9 matters differently in microsatellite-stable (MSS) tumors, which have intact DNA repair, versus microsatellite-instable (MSI) tumors, which do not. This pivot from encyclopedic collection to a disciplined, three-pillar validation strategy is itself the cycle’s key development.\n\nTo interrogate this hypothesis, the swarm is executing an orthogonal triad in which each pillar speaks a different biological language. First, it is harmonizing *cis-pQTLs*—naturally occurring genetic variants that alter how much PCSK9 protein a person produces—from two massive population biobanks (UK Biobank Pharma Proteomics Project and INTERVAL). Using *Mendelian randomization*, a technique that treats these genetic variants as natural experiments, the AI asks whether people born with lifelong higher or lower PCSK9 levels have different risks of developing MSS versus MSI colorectal cancer. Second, it is examining actual tumor tissue from patient datasets (TCGA and CPTAC-CRC) to see whether the same genetic variants control PCSK9 production inside tumors and whether these signals overlap with known inherited cancer risk, analyzed separately for MSS and MSI profiles. Third, it is mining CRISPR gene-editing screens from cancer cell lines (DepMap) to test whether knocking out PCSK9 kills cells with defective DNA repair (MSI-high) while sparing cells with intact repair machinery (MSS), which would reveal a subtype-specific vulnerability.\n\nThis tick yielded zero new empirical findings—no significant correlations, no hardened edges added to the graph. Yet this absence reflects scientific discipline rather than failure. The AI pruned numerous distracting threads that had accumulated in recent cycles—including unrelated rare-variant analyses and off-target repurposing candidates—and refined three hypotheses down to their testable core. By demanding convergence across population genetics, tumor biology, and functional genomics before declaring any relationship, the swarm is acknowledging that causal claims in human disease require more than a single suggestive statistic.\n\nLooking ahead, the open questions are precise and urgent. Will Mendelian randomization reveal directionally consistent causal estimates across at least two independent genome-wide association studies? Will *colocalization* analyses indicate that the same causal genetic variant drives both PCSK9 expression in tumor tissue and subtype-specific cancer susceptibility? And will the CRISPR data confirm that DNA-repair-deficient, MSI-high colorectal cancer lines are uniquely dependent on PCSK9 for survival? The next tick will pursue these three convergent tests. Only if all streams align will the mission advance PCSK9 from a speculative annotation to a hardened, molecularly stratified therapeutic hypothesis.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}